Home > Insider Trading > Filing (0001209191-23-012001)

Filing Details

Accession Number:: 0001209191-23-012001
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-22 20:05:55
Reporting Period:: 2023-02-18

Accepted Time:: 2023-02-22 20:05:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1567514	Intra-Cellular Therapies Inc.	ITCI	Pharmaceutical Preparations (2834)	364742850

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1756211	Mark Neumann	C/O Intra-Cellular Therapies, Inc. 430 East 29Th Street New York NY 10016	Evp, Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-02-18	11,139	$0.00	56,478	No	4	M	Direct
Common Stock	Disposition	2023-02-21	3,140	$46.61	53,338	No	4	S	Direct
Common Stock	Disposition	2023-02-21	123	$47.32	53,215	No	4	S	Direct
Common Stock	Disposition	2023-02-21	635	$48.93	52,580	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-02-18	11,139	$0.00	11,139	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Restricted stock units convert into common stock on a one-for-one basis.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.1267 to $47.1224, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.1591 to $47.5081, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.77 to $49.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.